NCT02788357View on ClinicalTrials.gov

Post-stroke Neural Plasticity With Atomoxetine

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2014

Conditions
Atomoxetine HydrochloridePlacebos
Interventions
DRUG

Atomoxetine

Subjects will receive a single daily oral dose of 40 mg of atomoxetine. We will administer 2 hours/daily of motor training sixty minutes after drug intake.

DRUG

Placebo

Subjects will receive a single daily oral dose of placebo. We will administer 2 hours/daily of motor training sixty minutes after drug intake.

All Listed Sponsors
lead

Lumy Sawaki

OTHER

NCT02788357 - Post-stroke Neural Plasticity With Atomoxetine | Biotech Hunter | Biotech Hunter